Rice University’s Han Xiao has been awarded the David W. Robertson Award for Excellence in Medicinal Chemistry by the American Chemical Society’s (ACS) Division of Medicinal Chemistry, recognizing Xiao’s pioneering contributions to therapeutic discovery.

U of A Comprehensive Cancer Center Director Dr. Dan Theodorescu plans to study loss of Y chromosome biology and investigate potential therapies for bladder and other cancers.

An innovative biotech startup founded by researchers at Washington University School of Medicine in St. Louis has been acquired by Lunit, a leading company in developing AI-based technologies for cancer prevention and early detection. The WashU startup, Prognosia, was created to develop software that harnesses AI to analyze mammograms and more accurately predict a woman’s five-year risk of developing breast cancer.

What happens when the relief of surviving brain cancer is accompanied by struggles to remember and concentrate, negatively impacting your quality of life? This is the unfortunate reality for many cancer survivors. But what if we could protect the brain from cancer-related cognitive impairment (CRCI)? Paving the way is a new study by UC Irvine researchers, including Munjal Acharya, An Do, Robert Krattli, and Andrea Tenner, along with Trent Woodruff of the University of Queensland. “We’ve identified a new, targeted way to protect the brain from the harmful side effects of cranial radiation therapy, a standard of care for brain cancers that often causes irreversible cognitive decline,” says Acharya. “This opens a realistic pathway to preserving quality of life for millions of brain cancer survivors currently facing this unmet medical need.” The findings appear in a paper published by the journal Cancer Research.

An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic.

A multicentre study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph’s Health Care London (Lawson), and University Health Network (UHN) has found a novel imaging solution, called prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scanning, can more effectively detect the recurrence of prostate cancer compared to standard imaging methods, and is associated with improved survival outcomes. The study, carried out over seven years, is published in The Journal of Nuclear Medicine. 

BUFFALO, NY – October 14, 2025 – A new research paper was published in Volume 16 of Oncotarget on October 13, 2025, titled “Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.”

PET-CT combines the functional information gained through PET with the structural details gained by a CT scan, aiding in early detection of recurrent disease.